IL6 and COVID-19: For instance, in a recent meta-analysis of 27 trials which “assessed the efficacy of Iterleukin-6 (IL-6) antagonists in patients hospitalized for COVID-19,” it was found that “administration of IL-6 antagonists (Tocilizumab and Sarilumab), compared with usual care or placebo, was associated with lower 28-day all-cause mortality” (13).